Compare ESPR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | IRWD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.5M | 741.8M |
| IPO Year | 2013 | 2010 |
| Metric | ESPR | IRWD |
|---|---|---|
| Price | $3.39 | $4.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $6.67 | $3.68 |
| AVG Volume (30 Days) | ★ 5.3M | 2.8M |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $303,802,000.00 | ★ $338,987,000.00 |
| Revenue This Year | $27.49 | N/A |
| Revenue Next Year | N/A | $37.22 |
| P/E Ratio | ★ N/A | $27.33 |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $0.69 | $0.53 |
| 52 Week High | $4.18 | $5.78 |
| Indicator | ESPR | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 51.79 |
| Support Level | $3.16 | $4.42 |
| Resistance Level | $3.64 | $4.91 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 61.94 | 16.15 |
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.